FR2558060A1 - NEW PHARMACEUTICAL FORMS CONTAINING DIPHOSPHONATES - Google Patents
NEW PHARMACEUTICAL FORMS CONTAINING DIPHOSPHONATES Download PDFInfo
- Publication number
- FR2558060A1 FR2558060A1 FR8500255A FR8500255A FR2558060A1 FR 2558060 A1 FR2558060 A1 FR 2558060A1 FR 8500255 A FR8500255 A FR 8500255A FR 8500255 A FR8500255 A FR 8500255A FR 2558060 A1 FR2558060 A1 FR 2558060A1
- Authority
- FR
- France
- Prior art keywords
- diphosphonates
- new pharmaceutical
- pharmaceutical forms
- forms containing
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000003076 Osteolysis Diseases 0.000 claims description 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002950 deficient Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- -1 Alkylidene diphosphonic acid Chemical compound 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- WMTIOGUVKBSEOW-UHFFFAOYSA-N ClC1(Cl)OP(=O)OP(=O)O1 Chemical class ClC1(Cl)OP(=O)OP(=O)O1 WMTIOGUVKBSEOW-UHFFFAOYSA-N 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- BMAWLNZSZXIPRQ-UHFFFAOYSA-N P(=O)(O)OP(=O)O.NC(CC)O Chemical class P(=O)(O)OP(=O)O.NC(CC)O BMAWLNZSZXIPRQ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'INVENTION A POUR OBJET UNE NOUVELLE COMPOSITION PHARMACEUTIQUE POUR L'ADMINISTRATION DE DIPHOSPHONATES, UTILE DANS LE TRAITEMENT DES ETATS DEFECTUEUX DU METABOLISME PHOSPHORE-CALCIUM. ELLE SE CARACTERISE EN CE QU'ELLE SE PRESENTE SOUS LA FORME DE SACHETS OU DE COMPRIMES, A DOSE UNIQUE, CONTENANT DES DIPHOSPHONATES DANS DES EXCIPIENTS PERMETTANT D'OBTENIR DES SOLUTIONS EFFERVESCENTES.THE OBJECT OF THE INVENTION IS A NEW PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATION OF DIPHOSPHONATES, USEFUL IN THE TREATMENT OF DEFECTIVE STATES OF THE PHOSPHORUS-CALCIUM METABOLISM. IT IS CHARACTERIZED IN THAT IT IS IN THE FORM OF SACHETS OR TABLETS, SINGLE-DOSE, CONTAINING DIPHOSPHONATES IN EXCIPIENTS ALLOWING TO OBTAIN EFFERVESCENT SOLUTIONS.
Description
Nouvelles formes pharmaceutiques contenant des diphosphonates.New pharmaceutical forms containing diphosphonates.
La présente invention concerne de nouvelles formes pharmaceutiques The present invention relates to new pharmaceutical forms
pour l'administration de diphosphonates. for the administration of diphosphonates.
Les diphosphonates sont une catégorie de composés récemnnt intro- Diphosphonates are a class of compounds originally introduced
duits dans la pratique thérapeutique pour traiter et corriger les états in the therapeutic practice to treat and correct the conditions
défectueux du métabolisme phosphore-calcium. defective phosphorus-calcium metabolism.
Divers documents ont été publiés sur l'activité des diphosphonates (étidronate de sodium, diphosphonates de dichlorométhylène, diphosphonates d'amino-hydroxy-propane, butane,pentane, hexane et similaires) pour inhiber la résorption osseuse qui est accentuée de façon anormale dans de nombreuses Various papers have been published on the activity of diphosphonates (sodium etidronate, dichloromethylene diphosphonates, amino-hydroxy-propane diphosphonates, butane, pentane, hexane and the like) to inhibit bone resorption which is abnormally accentuated in many
maladies osseuses telles que la maladie osseuse de Paget, les tumeurs osseu- bone diseases such as Paget's disease of bone, bone tumors
ses, la métastase osseuse provoquée par des tumeurs, ainsi que dans l'ostéoporose ou dans l'hyperparathyroïdisme, etc. Récemment, on a utilisé certains diphosphonates pour le traitement its, bone metastasis caused by tumors, as well as osteoporosis or hyperparathyroidism, etc. Recently, some diphosphonates have been used for the treatment
de l'ostéolyse métastatique.metastatic osteolysis.
Cette nouvelle possibilité d'application est le résultat d'études spécifiques concernant l'action des diphosphonates sur la résorption osseuse This new applicability is the result of specific studies on the action of diphosphonates on bone resorption
lors de l'ostéolyse tumorale; ces études ont débuté en 1977 et ort été en- during tumor osteolysis; These studies began in 1977 and have been
suite appliquées à des animaux (juin 1979) et finalement aux hommes. later applied to animals (June 1979) and finally to men.
L'utilisation des diphosphonates comme inhibiteurs de la résorption. The use of diphosphonates as inhibitors of resorption.
osseuse présente cependant des inconvénients certains, essentiellement en rapport avec l'absorption, que l'on peut résumer comme suit: a) faible degré d'absorption par administration par voie orale; However, this bone has certain disadvantages, essentially related to absorption, which can be summarized as follows: a) low degree of absorption by oral administration;
b) absorption non constante, variant dans le temps et d'un malade à un autPe. b) non-constant, time-varying absorption from one patient to another.
Ces difficultés d'absorption impliquent donc, pour l'administration These absorption difficulties therefore imply for the administration
par voie orale, l'utilisation de doses élevées, d'o difficulté pour la pré- orally, the use of high doses, difficulty in pre-
paration de gélules, de comprimés, etc. contenant des quantités très élevées paration of capsules, tablets, etc. containing very large amounts
de principe actif et très forte gêne pour les malades soumis à une administra- active ingredient and very severe discomfort for patients undergoing
tion continue de gélules et de comprimés provoquant des gastralgies pertur- capsules and tablets causing disturbed gastralgia.
batrices. On a maintenant trouvé de façon surprenante et c'est là l'objet de la présente invention, que les diphosphonates administrés sous forme de compositions effervescentes, font preuve d'une activité supérieure à celle batrices. It has now surprisingly been found, and this is the object of the present invention, that the diphosphonates administered in the form of effervescent compositions exhibit an activity greater than that
obtenue avec des concentrations égales du produit sous la forme de comprimés. obtained with equal concentrations of the product in the form of tablets.
Il en est probablement ainsi par suite de l'absorption gastro- This is probably the case as a result of gastric absorption.
intestinale accrue grâce à l'emploi d'un produit effervescent comme on increased intestinality through the use of an effervescent product as
peut le penser en raison de la présence dans l'urine des patients de con- This may be because of the presence in the urine of patients
centrations de phosphate supérieures à celles trouvées après l'administra- phosphate concentrations higher than those found after administration.
tion de diphosphonate sous forme de comprimés. Il est par conséquent évident que l'on peut réduire les doses et la fréquence d'administration si l'on utilise des compositions effervescentes, et on dispose ainsi d'un traitement plus aisé et bien toléré par les patients. Les concentrations en diphosphonates peuvent être différentes selon l'usage envisagé et selon le degré d'activité intrinsèque des différents diphosphonates et ces concentrations sont situées diphosphonate in the form of tablets. It is therefore obvious that the doses and frequency of administration can be reduced if effervescent compositions are used, and thus easier and well tolerated by patients. The diphosphonate concentrations may be different depending on the intended use and the degree of intrinsic activity of the different diphosphonates and these concentrations are located
dans la plage de 5 à 3000 mg par sachet à dose unique et par comprimé effer- in the range of 5 to 3000 mg per single-dose sachet per effervescent tablet.
vescent à dose unique.single dose vescent.
Les exemples suivants servent à illustrer les compositions selon l'invention sans aucunement en limiter la portée: The following examples serve to illustrate the compositions according to the invention without in any way limiting their scope:
Exemple 1Example 1
Comprimés effervescents Acides alkylidène-diphosphoniques mg 1000 Acide citrique anhydre mg 500 Carbonate de sodium anhydre mg 375 Bicarbonate de sodium (granulé) mg 525 Arôme naturel d'orange mg 5 Benzoate de sodium mg 95 Total mg 2500 2558060o Effervescent tablets Alkylidene diphosphonic acids mg 1000 Citric acid anhydrous mg 500 Sodium carbonate anhydrous mg 375 Sodium bicarbonate (granulated) mg 525 Natural orange flavor mg 5 Sodium benzoate mg 95 Total mg 2500 2558060o
Exemple 2Example 2
Granulés effervescents Acide alkylidène diphosphonique mg 1000 Carbonate de sodium anhydre mg 150 Bicarbonate de sodium mg 280 Saccharose mg 3888 Saccharinate de sodium mg 20 Acide citrique anhydre mg 700 Arôme d'orange anhydre mg 460 Arôme naturel d'orange mg 2 Total mg 6500 Effervescent granules Alphaidene diphosphonic acid mg 1000 Sodium carbonate anhydrous mg 150 Sodium bicarbonate mg 280 Saccharose mg 3888 Saccharin sodium mg 20 Citric acid anhydrous mg 700 Aroma of orange anhydrous mg 460 Natural flavor of orange mg 2 Total mg 6500
Exemple 3Example 3
Sachet à dose unique Acide alkylidène diphosphonique mg 200 Carbonate de sodium mg 30 Bicarbonate de sodium mg 55 Saccharinate de sodium mg 5 Acide citrique anhydre mg 140 Jus de citron anydre mg 90 Saccharose mg 229 Arôme naturel de citron mg 1 Total mg 750 Single-dose sachet Alkylidene diphosphonic acid mg 200 Sodium carbonate mg Sodium bicarbonate mg 55 Sodium saccharin mg 5 Citric acid anhydrous mg 140 Lemon juice anydre mg 90 Sucrose mg 229 Natural lemon flavor mg 1 Total mg 750
Claims (2)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT19122/84A IT1195993B (en) | 1984-01-12 | 1984-01-12 | PHARMACEUTICAL FORMS BASED ON DIPHOSPHONATES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2558060A1 true FR2558060A1 (en) | 1985-07-19 |
| FR2558060B1 FR2558060B1 (en) | 1988-02-19 |
Family
ID=11154925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8500255A Expired FR2558060B1 (en) | 1984-01-12 | 1985-01-09 | NOVEL PHARMACEUTICAL FORMS CONTAINING DIPHOSPHONATES |
Country Status (4)
| Country | Link |
|---|---|
| DE (1) | DE3500670A1 (en) |
| FR (1) | FR2558060B1 (en) |
| GB (1) | GB2153225B (en) |
| IT (1) | IT1195993B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0210728A2 (en) * | 1985-06-06 | 1987-02-04 | The Procter & Gamble Company | Kit containing polyphosphonate for treating osteoporosis |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3804686A1 (en) * | 1988-02-15 | 1989-08-24 | Henkel Kgaa | MEDICAMENT WITH A COMBINATION OF CYTOSTATIKA BZW. HORMONTHERAPEUTICS AND PHOSPHONOR DERIVATIVES |
| EP0939624B1 (en) * | 1996-05-17 | 2003-12-17 | Merck & Co., Inc. | Effervescent bisphosphonate formulation |
| EP1378234A1 (en) * | 1996-05-17 | 2004-01-07 | MERCK & CO. INC. | Effervescent bisphosphonate formulation |
| US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
| US7488496B2 (en) | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
| ES2448501T3 (en) * | 2002-03-06 | 2014-03-14 | Effrx Pharmaceuticals Sa | Effervescent compositions comprising bisphosphonates |
| ATE376444T1 (en) | 2002-05-10 | 2007-11-15 | Hoffmann La Roche | IBANDRONIC ACID FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS |
| BR0309691A (en) | 2002-12-20 | 2005-08-02 | Hoffmann La Roche | High dose ibandronate formulation |
| WO2006100527A1 (en) * | 2005-03-24 | 2006-09-28 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Effervescent tablet containing sodium alendronate and related use and process |
| KR20180115254A (en) | 2010-12-06 | 2018-10-22 | 에프락스 파머슈티컬즈 소시에떼 아노님 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2032M (en) * | 1962-05-25 | 1963-09-23 | Chugai Pharmaceutical Co Ltd | Effervescent composition for pharmaceutical use. |
| EP0015370A1 (en) * | 1979-02-13 | 1980-09-17 | Symphar S.A. | Diphosphonate or phosphate-phosphonate derivatives and pharmaceutical compositions containing them |
| US4234645A (en) * | 1977-03-29 | 1980-11-18 | The Procter & Gamble Company | Pharmaceutical composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2360797C2 (en) * | 1973-12-06 | 1985-05-23 | Henkel KGaA, 4000 Düsseldorf | Pharmaceutical preparations |
| DE2405254C2 (en) * | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body |
| GB2079285B (en) * | 1980-07-09 | 1984-05-23 | Symphar Sa | Dipthosphonate derivatives and pahrmaceutical compositions containing them |
| IT1194748B (en) * | 1981-02-12 | 1988-09-28 | Gentili Ist Spa | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOPATHIES |
| DE3225468A1 (en) * | 1982-07-05 | 1984-01-05 | Schering AG, 1000 Berlin und 4709 Bergkamen | Diphosphonic acid derivatives and pharmaceutical preparations containing them |
| DE3313049A1 (en) * | 1982-04-15 | 1983-11-17 | Istituto Gentili S.p.A., 56100 Pisa | Pharmacologically active biphosphonates, process for their preparation and pharmaceutical compositions containing them |
-
1984
- 1984-01-12 IT IT19122/84A patent/IT1195993B/en active
-
1985
- 1985-01-09 GB GB08500504A patent/GB2153225B/en not_active Expired
- 1985-01-09 FR FR8500255A patent/FR2558060B1/en not_active Expired
- 1985-01-11 DE DE19853500670 patent/DE3500670A1/en active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2032M (en) * | 1962-05-25 | 1963-09-23 | Chugai Pharmaceutical Co Ltd | Effervescent composition for pharmaceutical use. |
| US4234645A (en) * | 1977-03-29 | 1980-11-18 | The Procter & Gamble Company | Pharmaceutical composition |
| EP0015370A1 (en) * | 1979-02-13 | 1980-09-17 | Symphar S.A. | Diphosphonate or phosphate-phosphonate derivatives and pharmaceutical compositions containing them |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0210728A2 (en) * | 1985-06-06 | 1987-02-04 | The Procter & Gamble Company | Kit containing polyphosphonate for treating osteoporosis |
| EP0210728A3 (en) * | 1985-06-06 | 1989-06-07 | The Procter & Gamble Company | Kit containing polyphosphonate for treating osteoporosis |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2558060B1 (en) | 1988-02-19 |
| GB8500504D0 (en) | 1985-02-13 |
| GB2153225B (en) | 1987-08-05 |
| IT1195993B (en) | 1988-11-03 |
| DE3500670A1 (en) | 1985-07-18 |
| GB2153225A (en) | 1985-08-21 |
| IT8419122A0 (en) | 1984-01-12 |
| DE3500670C2 (en) | 1992-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2136281C1 (en) | Oral liquid pharmaceutical composition containing complex of paroxitine and amberlite irp-88 and method of treatment using this composition | |
| JP3344726B2 (en) | Anhydrous alendronate monosodium salt preparation | |
| EP0481294B1 (en) | Solid fast-dissolving pharmaceutical preparation containing S-(carboxymethyl)-L-cysteine and/or N-acetyl-cysteine | |
| RU2008103617A (en) | BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS | |
| SK147796A3 (en) | Pharmaceutical formulation and its use | |
| FR2558060A1 (en) | NEW PHARMACEUTICAL FORMS CONTAINING DIPHOSPHONATES | |
| RU98111594A (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN | |
| RU95102778A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for osseous tissue loss inhibition and serum cholesterol level decrease, pharmaceutical preparation containing 2-phenyl-3-aroylbenzothiophene | |
| EP0418043B1 (en) | Non-effervescent ibuprofen compositions | |
| GB2431579A (en) | Ramipril formulations | |
| JP3018160B2 (en) | Drug for reducing dysmenorrhea and / or premenstrual syndrome | |
| EP1784177B1 (en) | Formulation for l-tryptophane comprising carbidopa/benserazide | |
| EP0614366B1 (en) | Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours | |
| NZ334836A (en) | Liquid alendronate formulations and their use in preventing bone resorption | |
| Sethi et al. | Inconsistent response to divalproex sodium in hemichorea/hemiballism | |
| CA2376258A1 (en) | Oral preparations of etidronate disodium | |
| BE1012137A3 (en) | Bisphosphonates use in the preparation of dosage forms intended use a intramuscular. | |
| FR2580497A1 (en) | PHARMACEUTICAL COMPOSITIONS IN COMPRESSES | |
| KR19990023021A (en) | New medicinal uses | |
| DE4002825C2 (en) | Drug combination of a squalene synthetase inhibitor and another serum cholesterol lowering agent | |
| EP0695546A1 (en) | Powders based on metoclopramide and paracetamol or acetylsalicylic acid derivatives | |
| RU2182016C2 (en) | Spasmolytic composition, method to obtain spasmolytic composition | |
| JPS5942318A (en) | Therapeutical composition, manufacture and use | |
| EP1507542A2 (en) | Anti-cancer formulation | |
| EP0245954A2 (en) | Use of etodolac for lowering uric acid blood levels |